Fluidigm Corporation v. Ionpath

Background

Fluidigm asserted U.S. Patent Nos. 10,180,386 and 10,436,698 against Ionpath. The patents concern labeling cells with metal-tagged antibodies and analyzing those tags with mass spectrometry to identify analytes. Fluidigm alleged that Ionpath’s MIBIscope infringed the patents. The complaint also alleged intentional interference with contractual relations, but the court stated that claim was not at issue in this order.

The MIBIscope analyzes thin tissue slices mounted on slides. It uses a high-energy ion beam to scan small elements of the sample in rows, ionizing metal tags in each element for mass-spectrometry analysis. The system preserves location information and uses the results to create a map showing analytes across the sample.

Fluidigm moved for summary judgment of patent validity and infringement. Ionpath moved for summary judgment of noninfringement and invalidity and also sought to strike portions of Fluidigm’s evidence and expert report and material concerning allegedly untimely added accused products. The parties focused on Fluidigm’s Claim 9 of the ’386 patent and Ionpath’s Claim 6 of the ’698 patent, which the court described as substantially similar.

Claim construction

The central issue was the meaning of the word “sequentially” in the asserted claims. Fluidigm argued that the term required only detection at separate times, which it said the MIBIscope satisfied while scanning different portions of the sample. Ionpath argued that the term required complete, cell-by-cell analysis and therefore excluded the MIBIscope’s pixel-by-pixel scanning process.

The court adopted a hybrid construction. It held that “sequentially” requires detection at separate times, analysis on a cell-by-cell basis, and completion of a cell’s analysis before moving to the next cell. Under this construction, once a cell has been vaporized, atomized, ionized, and analyzed, the process is complete and does not return to that cell for another round of analysis.

The court relied on the claim language, the patents’ descriptions of sequentially introducing individual particles, and the prosecution history’s emphasis on single-cell analysis. It rejected Fluidigm’s argument that this construction improperly imported limitations from the specification, explaining that the term’s meaning had to be understood in light of the patents as a whole.

Literal infringement

The court held that the MIBIscope does not literally infringe the asserted claims. Although the MIBIscope scans different sample elements at separate times, the court found that it does not analyze complete cells one by one. Instead, it analyzes portions of multiple cells and may later return to portions of cells already scanned. The court also noted that the MIBIscope is minimally destructive and can permit later rescans, unlike the claimed process as construed by the court.

The court found that the distinction between whole-cell analysis and pixel-by-pixel tissue scanning was decisive. Fluidigm did not present an alternative theory of literal infringement in its motion or opposition to Ionpath’s motion.

Doctrine of equivalents

The doctrine of equivalents can establish infringement when an accused product does not literally satisfy a claim limitation but performs substantially the same function, in substantially the same way, to achieve substantially the same result. The court held that Fluidigm had not met its burden under the ensnarement doctrine, which prevents a patent owner from using equivalents to cover prior art.

The court explained that the required analysis begins with the patent owner’s proposed hypothetical claim that would literally cover the accused product. Fluidigm did not provide such a hypothetical claim despite having the opportunity to do so. The court therefore held that Fluidigm had abandoned this infringement theory.

Disposition

The court granted Ionpath’s motion for summary judgment in part and granted summary judgment of noninfringement of the asserted claims. The order did not reach most of the remaining noninfringement or invalidity arguments. It also did not reach Ionpath’s objections to portions of Fluidigm’s evidence, its motion to strike Fluidigm’s expert report, or its motion to strike the allegedly untimely addition of accused products. The court reserved sanctions and attorney-fee motions until final resolution of the case and set a further case-management conference.